LINC01477: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01477

NCBI ID: G101927900

LINC01477

Other Name(s): long intergenic non-protein coding RNA 1477 | Long intergenic non-protein coding RNA 1477

LINC01477: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01477 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarker properties. This RNA has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and survival. In this article, we will provide an overview of LINC01477, its potential drug targets, and its potential as a biomarker for various diseases.

Potential Drug Targets

LINC01477 has been shown to interact with several protein targets, including the protein SMAD4. SMAD4 is a key regulator of cell adhesion and has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. LINC01477 has been shown to regulate the expression of SMAD4, which suggests that it may be a potential drug target for these diseases.

Additionally, LINC01477 has also been shown to interact with the protein NF-kappa-B. NF-kappa-B is a signaling pathway that plays a critical role in inflammation, pain, and other cellular processes. LINC01477 has been shown to regulate the expression of NF-kappa-B, which suggests that it may also be a potential drug target for diseases that involve inflammation or pain.

Potential Biomarkers

LINC01477 has been shown to have potential as a biomarker for various diseases. For example, LINC01477 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This suggests that LINC01477 may be a potential biomarker for these diseases. Additionally, LINC01477 has been shown to be expressed in various tissues and cells, including cancer cells, which suggests that it may be a potential biomarker for cancer.

Drugs that target LINC01477 have the potential to treat various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, LINC01477 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancer. Targeting LINC01477 with drugs that enhance its expression or stability may have the potential to treat these cancers.

Conclusion

In conclusion, LINC01477 is a long intergenic non-protein-coding RNA that has potential as a drug target and biomarker for various diseases. Its interaction with protein targets such as SMAD4 and NF-kappa-B suggests that it may be a promising target for diseases that involve these processes. Additionally, its potential as a biomarker for various diseases makes it an attractive candidate for further research. Further studies are needed to determine the full potential of LINC01477 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1477

The "LINC01477 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01477 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets